Suppr超能文献

一种负载伊立替康的定制电纺药物递送系统,用于胰腺癌的局部和持续化疗药物释放

: A Customized Electrospun Drug Delivery System Loaded with Irinotecan for Local and Sustained Chemotherapy Release in Pancreatic Cancer.

作者信息

Cepeda-Franco Carmen, Mitxelena-Iribarren Oihane, Calero-Castro Francisco José, Astigarraga Malen, Castillo-Tuñon Juan M, Laga Iman, Pereira Sheila, Arana Sergio, Mujika Maite, Padillo-Ruiz Javier

机构信息

Department of General Surgery, Virgen del Rocio University Hospital, 41013 Seville, Spain.

Oncology Surgery, Cell Therapy, and Organ Transplantation Group, Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, University of Seville, 41013 Seville, Spain.

出版信息

Bioengineering (Basel). 2023 Feb 1;10(2):183. doi: 10.3390/bioengineering10020183.

Abstract

Post-surgical chemotherapy in pancreatic cancer has notorious side effects due to the high dose required. Multiple devices have been designed to tackle this aspect and achieve a delayed drug release. This study aimed to explore the controlled and sustained local delivery of a reduced drug dose from an irinotecan-loaded electrospun nanofiber membrane (named ) that can be placed on the patients' tissue after tumor resection surgery. The drug delivery system formulation was made of polycaprolactone (PCL). The mechanical properties and the release kinetics of the drug were adjusted by the electrospinning parameters and by the polymer ratio between 10 w.t.% and 14 w.t.% of PCL in formic acid:acetic acid:chloroform (47.5:47.5:5). The irinotecan release analysis was performed and three different release periods were obtained, depending on the concentration of the polymer in the dissolution. The device was tested in 2D and 3D cell cultures and it demonstrated a decrease in cell viability in 2D culture between 72 h and day 7 from the start of treatment. In 3D culture, a decrease in viability was seen between 72 h, day 7 ( < 0.001), day 10 ( < 0.001), 14 ( < 0.001), and day 17 ( = 0.003) as well as a decrease in proliferation between 72 h and day 10 ( = 0.030) and a reduction in spheroid size during days 10 ( = 0.001), 14 ( < 0.001), and 17 ( < 0.001). In conclusion, showed a successful encapsulation of a chemotherapeutic drug and a sustained and delayed release with an adjustable releasing period to optimize the therapeutic effect in pancreatic cancer treatment.

摘要

由于胰腺癌术后化疗所需剂量较高,其副作用声名狼藉。人们设计了多种装置来解决这一问题并实现药物的延迟释放。本研究旨在探索从载有伊立替康的电纺纳米纤维膜(命名为 )中以降低的药物剂量进行可控且持续的局部给药,该膜可在肿瘤切除手术后放置于患者组织上。药物递送系统制剂由聚己内酯(PCL)制成。通过电纺参数以及在甲酸:乙酸:氯仿(47.5:47.5:5)中PCL的10重量%至14重量%之间的聚合物比例来调节药物的机械性能和释放动力学。进行了伊立替康释放分析,根据溶解中聚合物的浓度获得了三个不同的释放期。该 装置在二维和三维细胞培养中进行了测试,结果表明在二维培养中,从治疗开始72小时至第7天细胞活力下降。在三维培养中,在72小时、第7天(<0.001)、第10天(<0.001)、第14天(<0.001)和第17天(=0.003)观察到活力下降,以及在72小时至第10天(=0.030)增殖下降,并且在第10天(=0.001)、第14天(<0.001)和第17天(<0.001)球体大小减小。总之, 显示出成功包封了一种化疗药物,并具有持续且延迟的释放,释放期可调节,以优化胰腺癌治疗的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e8e/9952015/1c9164a46c54/bioengineering-10-00183-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验